Ovarian Cancer Metastasis and Tumor Evolution: A Survey

Abstract

Ovarian cancer remains a formidable public health challenge due to its high mortality rate, often attributed to late-stage diagnosis and limited therapeutic options. This survey explores key aspects of ovarian cancer, focusing on metastasis, tumor evolution, and the tumor microenvironment. Metastasis, responsible for most cancer-related deaths, involves the dissemination of cancer cells from the primary tumor to distant sites, facilitated by the tumor microenvironment and pre-metastatic niches. Tumor evolution, marked by genetic and phenotypic changes, contributes to treatment resistance and intratumor heterogeneity. The tumor microenvironment plays a crucial role in cancer progression, influencing immune modulation and therapeutic resistance. Cancer stem cells and metastasis-initiating cells are pivotal in tumor heterogeneity and metastasis, complicating treatment strategies. The survey highlights the importance of understanding these processes to develop innovative diagnostic and therapeutic approaches. Recent advancements in artificial intelligence and machine learning offer promise for early detection and personalized treatment strategies. The integration of biomarkers and predictive models enhances the understanding of metastatic mechanisms, providing opportunities for targeted interventions. Future research should focus on developing novel biomarkers, refining predictive models, and exploring therapeutic targets within the tumor microenvironment to improve clinical outcomes for ovarian cancer patients.

1 Introduction

1.1 Significance of Ovarian Cancer

Ovarian cancer is a critical public health issue, consistently ranking among the deadliest gynecological malignancies globally. Its high mortality rate is largely attributed to late-stage diagnosis, as initial symptoms are often vague and non-specific, leading to delayed detection. Consequently, many cases are diagnosed at advanced stages, severely limiting therapeutic options and contributing to poor 5-year survival rates [1]. The incidence of ovarian cancer varies regionally, with rising rates placing increasing demands on healthcare systems. This underscores the urgent need for improved diagnostic and prognostic tools, particularly effective early detection methodologies. Understanding the etiology and risk factors of ovarian cancer is essential for developing targeted interventions that aim to enhance patient outcomes and reduce the disease's public health impact. Additionally, addressing the challenge of designing neural network architectures that optimize both accuracy and computational efficiency is vital for advancing innovative diagnostic solutions [2].

1.2 Importance of Understanding Metastasis and Tumor Evolution

Investigating metastasis and tumor evolution is crucial for improving outcomes in ovarian cancer, as these processes are central to the disease's lethality and complexity. Metastasis, which accounts for the majority of cancer-related deaths, involves the dissemination of cancer cells from the primary tumor to distant sites, often facilitated by pre-metastatic and metastatic niches that provide



Figure 1: chapter structure

favorable environments for colonization. This highlights the need for targeted interventions to inhibit cancer spread. The complexities of the metastatic process necessitate a deeper understanding of the interactions between cancer cells and local tissues [3].

Tumor evolution, marked by genetic and phenotypic changes, significantly contributes to intratumor heterogeneity and adaptive resistance, complicating treatment strategies [4]. The chaotic nature of tumor evolution, which current models struggle to capture accurately, further complicates patient management [5]. This complexity is intensified by late-stage diagnoses and chemoresistance, emphasizing the need for innovative diagnostic and prognostic tools. The integration of artificial intelligence (AI) and machine learning (ML) into ovarian cancer diagnostics holds promise for enhancing early detection and personalizing treatment, potentially improving clinical outcomes.

Moreover, understanding the plasticity of molecular networks can lead to more effective anti-cancer therapies tailored to specific cancer development stages [6]. The tumor immune microenvironment (TIME) is also critical for improving therapeutic outcomes, especially concerning immunotherapy [7]. By exploring the mechanisms of metastasis and tumor evolution, we can refine predictive models and therapeutic strategies, ultimately enhancing treatment efficacy and survival rates for ovarian cancer patients.

1.3 Structure of the Survey

This survey offers a comprehensive examination of ovarian cancer, emphasizing metastasis and tumor evolution, structured into several key sections. The introduction outlines the significance of ovarian cancer as a major public health concern and underscores the necessity of understanding its metastatic

and evolutionary dynamics. Following this, the background and core concepts section provides foundational definitions and explanations of essential terms such as ovarian cancer, metastasis, tumor evolution, and the tumor microenvironment, establishing a basis for subsequent discussions.

The survey progresses to a detailed analysis of the mechanisms underlying metastasis in ovarian cancer, elucidating the biological processes, metabolic adaptations, and cellular interactions that enable cancer cells to disseminate and establish secondary tumors. This includes an exploration of how cancer cells alter their metabolism during the metastatic cascade, the tumor microenvironment's role in facilitating these processes, and the implications for therapeutic targeting of unique metabolic traits exhibited by metastatic cells compared to their primary tumor counterparts [8, 9]. The analysis then shifts to tumor evolution, focusing on genetic and phenotypic changes, tumor heterogeneity, and the roles of cancer stem cells and metastasis-initiating cells in disease progression.

Subsequently, the survey examines the tumor microenvironment (TME), detailing its metabolic interactions, immune modulation mechanisms, and potential therapeutic targets. The TME, comprising various non-cancerous cells such as fibroblasts, immune cells, and adipocytes, significantly influences tumor initiation, progression, and metastasis through complex signaling pathways and interactions with the tumor vasculature, presenting opportunities for innovative therapeutic strategies aimed at manipulating these components to enhance treatment efficacy [10, 11, 12, 13, 14]. The concept of the metastatic niche is also explored, focusing on the formation and maintenance of these niches along with the use of biomarkers and predictive models.

The survey culminates in a discussion of treatment implications, addressing challenges in detection and treatment, mechanisms of drug resistance, and innovative therapeutic approaches. Strategies for targeting cancer stem cells and altering tumor dynamics are also considered. The conclusion synthesizes critical findings from recent research on ovarian cancer, emphasizing the urgent need for continued investigation into this lethal gynecologic malignancy. It highlights emerging trends in treatment modalities, including the increasing use of maintenance therapies and the integration of artificial intelligence in diagnostics, while identifying future research directions aimed at enhancing early detection, improving treatment efficacy, and ultimately achieving better patient outcomes for those battling ovarian cancer, a disease often characterized by late-stage diagnosis and high recurrence rates [15, 16, 17, 18].The following sections are organized as shown in Figure 1.

2 Background and Core Concepts

2.1 Ovarian Cancer and Risk Factors

Ovarian cancer is a complex malignancy, divided into Type I and Type II tumors, each with distinct biological and clinical profiles. Type I tumors, including low-grade serous, endometrioid, clear cell, and mucinous carcinomas, are generally indolent, whereas Type II tumors, primarily high-grade serous carcinomas (HGSOC), are aggressive and account for most ovarian cancer deaths. The disease's etiology is multifactorial, involving genetic predispositions such as BRCA1 and BRCA2 mutations, hormonal influences, and the breakdown of multicellular genetic constraints crucial for tumor development [19].

Epidemiologically, ovarian cancer poses significant challenges, notably due to late-stage diagnoses stemming from asymptomatic early disease and limited diagnostic methods. The lack of effective biomarkers and reliable screening tools complicates differentiation between malignant and benign tumors, hindering early detection [20]. Tumor heterogeneity further complicates diagnosis and treatment [21]. Moreover, the metastatic process is inefficient, with few cancer cells forming secondary tumors, complicating patient management [3].

Risk assessment is influenced by reproductive history, lifestyle factors, age, and family history [22, 23]. The genetic heterogeneity of ovarian cancer complicates the identification of effective drug targets, posing challenges for therapeutic development [24]. However, advancements in AI and machine learning hold promise for improving early detection and risk assessment, despite traditional algorithms' limitations in accurately defining risk factors. A deeper understanding of cancer cell population dynamics and proteomic patterns can further elucidate ovarian cancer pathogenesis and risk factors.

2.2 Metastasis and Metastatic Niche

Metastasis is a complex, multistep process where cancer cells spread from a primary tumor to establish secondary tumors in distant organs [25]. This process involves local invasion, intravasation, survival in circulation, extravasation, and colonization [8]. The metastatic cascade is the leading cause of cancer mortality, allowing cancer cells to thrive in organs often inaccessible to conventional therapies [26].

Central to metastasis is the concept of the metastatic niche, particularly the pre-metastatic niche (PMN), which involves microenvironmental changes in distant organs that facilitate tumor cell colonization [27]. These niches are shaped by tumor-secreted factors, the extracellular matrix (ECM), immune cells, and stromal components, creating a favorable environment for cancer cell colonization [28]. Myeloid-derived suppressor cells (MDSCs) play a crucial role in establishing PMNs by modulating the immune landscape [29].

Exosomes and extracellular vesicles influence PMN formation by transporting molecular signals from the primary tumor to distant tissues, altering the local microenvironment [30]. Organ-specific metastasis is facilitated by these pre-metastatic changes, allowing primary tumors to create conducive environments in distant organs [31].

Despite advances in understanding these processes, current screening methods for metastasis detection, particularly for high-grade serous carcinomas, remain inadequate. Existing diagnostic tools exhibit low sensitivity and specificity, and the intricate interactions between tumor cells and the microenvironment are not fully captured by current mathematical models, limiting the ability to predict metastatic behavior and develop effective interventions [32].

2.3 Tumor Microenvironment (TME)

The tumor microenvironment (TME) is a complex ecosystem that significantly impacts cancer development, progression, and therapeutic resistance. It comprises diverse cellular and non-cellular components, including cancer cells, cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), immune cells, and the extracellular matrix (ECM). Interactions among these components foster a milieu that supports tumor growth and metastasis [33].

A critical feature of the TME is its immunosuppressive nature, which impedes immune cell activity, allowing tumors to evade immune surveillance [10]. Characterization of the tumor immune microenvironment (TIME) reveals crucial interactions between immune and cancer cells for therapeutic implications [7]. In ovarian cancer, immune cell spatial interactions within the TME correlate with patient outcomes, underscoring their importance for improving prognostic and therapeutic strategies [34].

Hypoxia within the TME exacerbates the immunosuppressive environment by affecting CAFs and blood vessels, promoting conditions conducive to cancer progression [35]. Hypoxia also drives tumor angiogenesis, critical for tumor growth and metastasis, by inducing the release of tumor angiogenic factors (TAFs) [36]. This process is vital for supplying necessary nutrients and oxygen to the tumor, facilitating its expansion.

Metabolic dynamics within the TME are pivotal, involving competition for nutrients such as glucose and glutamine between cancer and immune cells, shaping an environment that promotes tumor growth [10]. Additionally, spatial heterogeneity in drug concentrations within the TME significantly influences therapeutic resistance, posing challenges for effective cancer treatment [37].

Tumor-derived exosomes and their miRNA content modulate the TME, affecting communication between tumor cells and their surroundings [38]. These exosomes facilitate molecular signal transfer that can alter recipient cell behavior within the TME, promoting tumor growth and metastasis [38].

Understanding the intricacies of the TME is essential for developing targeted therapies that disrupt supportive interactions within this environment. Strategies such as modulating TAM activity or targeting ECM remodeling show promise for enhancing therapeutic outcomes. Advanced computational models, like the Cellular Potts Model (CPM), provide insights into the spatial and relational dynamics of the TME by simulating cell interactions [39]. Addressing the complexities of the TME can lead to novel therapeutic strategies to combat cancer progression and metastasis [33].

2.4 Cancer Biology and Stem Cells

The landscape of cancer biology in ovarian cancer is shaped by genetic, epigenetic, and environmental factors driving tumor initiation, progression, and metastasis [40]. Central to these processes are cancer stem cells (CSCs), which contribute to tumor heterogeneity, metastasis, and therapeutic resistance. CSCs possess the unique ability to self-renew and differentiate, sustaining tumor growth and facilitating recurrence post-treatment [40].

The dualistic nature of ovarian cancer, particularly the distinction between Type I and Type II tumors, necessitates targeting CSCs in developing effective therapeutic strategies. High-grade serous carcinomas (HGSOC), representative of Type II tumors, are notably aggressive and resistant to conventional therapies, largely due to CSCs' resilience against chemotherapy, enabling tumor repopulation and metastasis [41].

Interactions between CSCs and the TME significantly impact treatment efficacy. Tumor-associated macrophages (TAMs), a prevalent immune cell type within the TME, influence tumor progression and immune response dynamics. The supportive role of CAFs and stromal components provides structural and biochemical support to CSCs, promoting tumor progression and resistance. The hybrid epithelial/mesenchymal (E/M) phenotype associated with CSCs is crucial in cell-fate decisions during tumorigenesis and metastasis, underscoring the complexity of cancer biology in ovarian cancer [41].

Genomic alterations, including those affecting oncogenes and tumor suppressor genes, further define the CSC phenotype and drive cancer evolution. The chaotic multi-scale cancer-invasion model (CMSCIM) integrates nonlinear coupling and chaotic dynamics to describe tumor growth and metastasis, emphasizing the role of cancer biology in tumor evolution [5]. This model highlights the importance of understanding the chaotic and dynamic nature of tumor evolution in developing effective therapeutic interventions.

Emerging treatment protocols for ovarian cancer increasingly focus on specifically targeting CSCs and addressing drug resistance mechanisms, essential for enhancing patient outcomes. This approach includes integrating novel therapies such as PARP inhibitors, antiangiogenic agents like bevacizumab, and exploring biomarkers that predict treatment responses, paving the way for more personalized and effective management of this highly lethal disease [42, 43, 17]. Innovative approaches that simulate the complex dynamics of CSCs within tumors are crucial for understanding tumor growth kinetics and devising effective therapeutic strategies. By focusing on the unique properties of CSCs and their interactions with the TME, researchers can develop targeted therapies that address the root causes of ovarian cancer aggressiveness and recurrence, ultimately improving patient outcomes and survival rates.

3 Mechanisms of Metastasis in Ovarian Cancer

3.1 Biological Processes of Metastasis

Metastasis, a critical factor in the lethality of ovarian cancer, involves the spread of cancer cells from the primary tumor to distant sites. This process begins with local invasion, where cells penetrate the basement membrane and invade surrounding tissues, facilitated by the epithelial-mesenchymal transition (EMT) [44]. EMT endows cancer cells with mesenchymal traits, enhancing their motility and invasiveness, while the hybrid epithelial/mesenchymal (E/M) phenotype allows cells to retain epithelial traits, aiding metastasis [45].

As illustrated in Figure 2, the figure highlights the key biological processes involved in metastasis, emphasizing the stages of local invasion through EMT and hybrid E/M phenotypes. Subsequently, cancer cells intravasate into the circulatory system as circulating tumor cells (CTCs), evading immune surveillance by clustering with platelets and leukocytes [46]. Their ability to navigate chemical gradients is vital for extravasation and colonization of distant tissues, influenced by physicochemical cues within the tumor microenvironment (TME) [47]. Upon reaching distant sites, CTCs adapt to new microenvironments shaped by interactions with stromal cells, immune components, and extracellular matrix (ECM) elements [48]. The acidic microenvironment, characterized by elevated H+ ion concentrations, destabilizes normal cell populations, enhancing cancer cell survival [49].

The metastatic niche, a specialized environment conducive to cancer cell colonization, is established through complex TME interactions [30]. Computational models, such as those simulating surface

charge density at the tumor-tissue interface, provide insights into biophysical factors influencing metastasis [50]. Hybrid mathematical models analyze combination therapies' effects on secondary lesions, emphasizing genomic mutations and immunogenicity in treatment outcomes [51].

Advanced computational approaches, including agent-based models and persistent homology, elucidate intricate spatial relationships and dynamics within the TME, enhancing understanding of metastasis [52]. Integrating these insights with genomic and clinical data aims to improve early detection and therapeutic strategies for ovarian cancer. Understanding these processes is crucial for developing interventions that disrupt the metastatic cascade, improving patient outcomes.

Cancer metastasis dynamics vary among patients, reflecting the complexity of underlying biological processes [53]. The universal growth law for solid tumors may impact understanding of processes enabling metastasis [54]. Current models' inadequacies in predicting outcomes in complex systems underscore the need for sophisticated approaches [55]. Integrating biological laws into models, particularly regarding vascularization, offers a more accurate representation of tumor growth dynamics [56]. The transition between collective and individual cancer cell invasion strategies remains complex [57]. Quantitative analysis of tumor metastasis development is essential for optimizing therapeutic control strategies [58]. The formation of motile cell clusters in primary tumors, particularly their aggregation before detachment and metastasis, is a significant research area [39]. Viewing metastasis as a dynamic process involving bidirectional migration of cancer cells offers a novel perspective on dissemination [59].

A model combining a renewal equation for metastasis density with an ODE model for tumor growth enhances understanding of metastatic evolution [60]. Integrating somatic mutation data to assess clonal relatedness between tumor pairs is crucial for understanding metastasis [61]. Malignant transformation is a two-phase phenomenon where early tumor-initiating cells exhibit increased plasticity, while late-stage cancer cells show decreased plasticity, complicating treatment strategies [6]. Insights into angiogenesis mechanisms have identified key factors promoting tumor growth and potential therapeutic targets [36].



Figure 2: This figure illustrates the key biological processes involved in metastasis, highlighting the stages of local invasion through EMT and hybrid E/M phenotypes, the role of the circulatory system in CTCs evasion and chemical gradient navigation, and the establishment of the metastatic niche through TME interactions and acidic microenvironments.

3.2 Metabolic and Biophysical Influences

Metabolic and biophysical influences are critical in shaping the metastatic progression of ovarian cancer, dictating how cancer cells adapt to diverse microenvironments. Metabolic reprogramming, a hallmark of malignancy, enables cancer cells to meet energetic and biosynthetic demands for rapid proliferation and invasion, enhancing metastatic potential. This adaptation is linked to EMT, facilitating cancer cell detachment and migration [62].

Biophysical interactions within the TME further modulate cancer cell behavior. Mechanical forces and the physical architecture of the TME, including the ECM, influence cell migration and invasion. Mechanical interactions between adjacent cancer cells enhance transmigration speed, highlighting the significance of physical proximity and mechanical properties of the matrix in metastatic efficiency. Current models often fail to adequately account for these dynamic interactions, highlighting a critical gap in understanding [59].

The complexity of cancer cell migration is compounded by the ability of tumor cells to switch between amoeboid and mesenchymal migration modes, a plasticity influenced by ECM structure and chemotactic gradients [63]. This switching behavior complicates modeling of invasion, as existing models struggle to represent the diverse and plastic nature of migration mechanisms [57]. The tortuosity of blood vessels within the TME imposes additional constraints, significantly influencing tumor evolution and highlighting the importance of considering both genetic and non-genetic factors in cancer progression [64].

Interactions within the tumor immune microenvironment (TIME), particularly macrophage behavior, play a crucial role in tumor dynamics. Enhanced agent-based models simulate these interactions, focusing on macrophage behavior and its impact on progression [10]. However, existing methods often struggle to capture the dynamic nature of tumor-immune interactions, particularly in predicting early signs of escape and metastasis [65].

Innovative approaches integrating preprocessing algorithms like principal component analysis (PCA) and genetic algorithms with classification algorithms have shown promise in enhancing detection of metastatic cancer, underscoring the potential for computational models to improve understanding of metastatic dynamics [66]. By unraveling complex interactions between metabolic and biophysical factors, researchers can develop more effective therapeutic strategies targeting cancer cells' vulnerabilities in metastasizing and colonizing distant organs.

3.3 Cellular and Molecular Interactions

Intricate cellular and molecular interactions within the TME are fundamental to metastasis, facilitating dissemination and colonization of cancer cells in distant organs. Myeloid-derived suppressor cells (MDSCs) are particularly influential in pre-metastatic niche (PMN) formation, exerting effects through immunosuppression, inflammation, and ECM remodeling [29]. These mechanisms prepare distant sites for colonization, highlighting MDSCs as potential therapeutic targets in mitigating metastasis.

The interaction between cancer cells and the stromal environment is facilitated by a complex network of signaling molecules like cytokines, growth factors, and chemokines. These molecules remodel the ECM and recruit supportive stromal and immune cells, contributing to a chronically inflamed TME, where cancer cells, immune cells, and stroma promote tumorigenic phenotypes and facilitate metastasis [33, 67]. The ECM participates in signaling cascades regulating cell adhesion, migration, and survival, playing a pivotal role in metastasis.

Interactions between tumor cells and immune components within the TME are complex. Tumor-associated macrophages (TAMs) can exhibit pro-tumorigenic or anti-tumorigenic phenotypes depending on microenvironmental cues. The polarization of TAMs towards a pro-tumorigenic M2 phenotype is influenced by tumor-derived factors, promoting immune evasion and facilitating metastasis by creating a supportive PMN. This niche is established through recruitment of various immune cells, including neutrophils, which can enhance or inhibit metastasis depending on activation status. These dynamic interactions play a crucial role in cancer progression and invasion [68, 69]. This immunosuppressive milieu is compounded by regulatory T cells and other elements that dampen anti-tumor responses.

The molecular dialogue between cancer cells and mesenchymal stem cells (MSCs) within the TME contributes to progression and metastasis. MSCs migrate to the TME, differentiating into cancer-associated fibroblasts (CAFs), which modify the ECM and secrete growth factors and cytokines that enhance tumor growth, promote angiogenesis, and facilitate metastasis. This interaction influences tumor structural integrity and treatment response, underscoring the importance of stromal components, particularly collagens, in progression and potential for using collagen-derived biomarkers to assess tumor reactivity and predict outcomes [70, 67]. These interactions underscore the complexity of cellular and molecular networks within the TME driving metastasis.

A comprehensive understanding of intricate cellular and molecular interactions facilitating metastasis is essential for developing targeted therapies aimed at disrupting the metastatic cascade, characterized by tumor cell motility, invasion, and adaptation to microenvironments, contributing to cancer morbidity and mortality. By elucidating biological mechanisms underpinning these interactions, researchers can identify therapeutic windows for effective intervention in metastatic disease [27, 8, 71, 25, 72].

Targeting key players such as MDSCs and TAMs, while modulating the ECM and signaling pathways within the TME, may impede metastasis and improve clinical outcomes for ovarian cancer patients.

In recent years, the understanding of cancer progression has evolved significantly, particularly in relation to the intricate mechanisms underlying tumor evolution. This complexity is well-represented in Figure 3, which illustrates the hierarchical structure of tumor evolution and genetic changes. The figure encompasses a range of factors including genetic and epigenetic modifications, tumor heterogeneity, and evolution models, as well as the critical roles played by cancer stem cells (CSCs) and metastasis initiating cells (MICs). It highlights key categories and subcategories, emphasizing the interplay between genetic alterations, epigenetic dynamics, tumor microenvironment interactions, and modeling approaches. Such a comprehensive depiction is essential for understanding the multifaceted nature of cancer progression and the development of effective therapeutic strategies.



Figure 3: This figure illustrates the hierarchical structure of tumor evolution and genetic changes, encompassing genetic and epigenetic modifications, tumor heterogeneity and evolution models, and the role of cancer stem cells (CSCs) and metastasis initiating cells (MICs). It highlights key categories and subcategories, emphasizing the interplay between genetic alterations, epigenetic dynamics, tumor microenvironment interactions, and modeling approaches in understanding cancer progression and therapeutic strategies.

4 Tumor Evolution and Genetic Changes

4.1 Genetic and Epigenetic Modifications

Genetic and epigenetic modifications are pivotal in the evolution of ovarian cancer, impacting tumor progression, heterogeneity, and resistance to treatment. Mutations in oncogenes and tumor suppressor genes activate oncogenic pathways, leading to genomic instability and heterogeneity. Advances in cancer genome sequencing have revealed complex mechanisms like chromothripsis and kataegis, which significantly influence cancer development and metastasis. Pathway analysis and computational frameworks have enhanced our understanding of mutations and copy number variations, though they represent only a subset of the genomic changes in tumors [73, 74, 46]. This genomic landscape contributes to intratumor heterogeneity, complicating treatment and highlighting the need for personalized strategies.

Epigenetic changes, including DNA methylation, histone modifications, and non-coding RNA expression, regulate gene expression by altering chromatin structure without changing the DNA sequence. These modifications are crucial in cancer, where genomic instability and clonal evolution drive tumor complexity [73, 46]. Epigenetic changes enable cancer cells to quickly adapt to environmental and therapeutic pressures, complicating treatment strategies. The interplay between genetic and

epigenetic modifications is complex, with epigenetic changes modulating mutated gene expression and exacerbating tumor progression and resistance.

The tumor microenvironment (TME) plays a significant role in these evolutionary processes. Hypoxia, mediated by hypoxia-inducible factors (HIFs), modulates genetic and epigenetic landscapes, influencing tumor adaptation and progression. Interactions within the TME, including immune and stromal components, further impact tumor evolution. High-resolution techniques are crucial for elucidating the spatial and functional characteristics of immune cells in the TME, providing insights into tumor-immune dynamics and potential therapeutic targets [7].

Despite progress, challenges remain in early detection and biomarker development, particularly for high-grade serous carcinomas. Innovative modeling approaches, such as the Multiscale Moving Boundary Model, emphasize the reciprocal influence between macro-scale tumor dynamics and micro-scale enzyme activity, highlighting interactions among tumor cells, the extracellular matrix (ECM), and matrix-degrading enzymes [69, 75, 76, 57]. These models enhance understanding of genetic and epigenetic roles in tumor evolution, capturing the interplay between tissue-scale morphology changes and molecular dynamics of enzymes like urokinase plasminogen activator (uPA).

Theoretical frameworks challenging traditional views, such as the Somatic Mutation Theory, propose many mutations in cancer cells are passenger mutations rather than drivers, prompting reevaluation of the genetic landscape in cancer. Cutting-edge genomic technologies and advanced computational modeling aim to unravel interactions driving tumor evolution, focusing on genomic instability and heterogeneity. A comprehensive understanding of clonal heterogeneity and mechanisms behind genomic alterations, including chromothripsis and kataegis, is vital for developing personalized treatment strategies addressing cancer complexities [73, 46]. Understanding these genetic and epigenetic dynamics is essential for devising interventions that disrupt the metastatic cascade and improve patient outcomes.

4.2 Tumor Heterogeneity and Evolution Models

Tumor heterogeneity, driven by genetic, epigenetic, and environmental influences, complicates cancer treatment by affecting therapeutic response and resistance [77]. Understanding these dynamics is crucial for developing effective therapies, leading to various models elucidating underlying mechanisms. Figure 4 illustrates the hierarchical structure of tumor heterogeneity and evolution models, emphasizing these influences, various tumor evolution models, and the therapeutic implications of these insights.

Recent modeling advancements highlight spatial and mechanical factors in tumor evolution. The Cellular Potts model offers insights into cell interactions and motility within a 2D lattice representation of a tumor, capturing complexities of collective cell invasion [78]. This model emphasizes short-range migration and cell turnover in facilitating rapid cell mixing and tumor evolution [79].

Incorporating multicellularity-related genes into tumor evolution studies provides a framework for understanding their roles in driving heterogeneity and evolution [19]. This perspective underscores the importance of genetic and cellular variations within tumors for progression and adaptation. Mathematical models quantifying heterogeneity of stem cells (SC), cancer stem cells (CSC), and cancer itself by integrating genetic and epigenetic factors offer a comprehensive approach to understanding tumor heterogeneity [80].

Various models of tumor evolution, including linear, branching, neutral, and punctuated models, may operate concurrently and evolve during tumor progression, reflecting the complexity of tumor dynamics [81]. Hybrid multiscale models integrating partial and stochastic differential equations provide a comprehensive approach to modeling the spatiotemporal evolution of cancer cells [57]. These models consider the interplay between mechanical interactions and biochemical signaling pathways, offering nuanced insights into tumor heterogeneity and evolution.

The established role of hypoxia and hypoxia-inducible factors (HIFs) in cancer biology has led to potential therapeutic targets [35]. Hypoxia influences genetic and epigenetic landscapes of tumors, contributing to heterogeneity and resistance. Reducing complex models to manageable systems, such as condensing a 24-dimensional model to a four-dimensional monotone system, allows for rigorous analysis using monotone dynamical systems theory, enhancing understanding of tumor evolution [44].

The integration of artificial intelligence (AI) into cancer research has expanded tumor modeling capabilities. AI models, categorized into diagnostic and prognostic types, enhance predictions of malignancy status, treatment response, and overall survival [15]. However, significant gaps remain in research addressing prediction, prevention, and AI assurance in cancer data analysis [18].

By exploring various cancer models, researchers aim to elucidate the intricate dynamics of tumor heterogeneity and evolutionary processes, crucial for understanding the genomic instability and clonal diversity characterizing cancer. This exploration enhances comprehension of tumor biology and informs the development of personalized and targeted therapies, leveraging insights from advanced techniques such as single-cell "omics" and deep learning approaches that integrate biological knowledge for improved interpretability in precision medicine [82, 83, 46]. These models deepen understanding of cancer dynamics and provide insights into developing more effective therapeutic strategies.



Figure 4: This figure illustrates the hierarchical structure of tumor heterogeneity and evolution models, emphasizing genetic, epigenetic, and environmental influences, various tumor evolution models, and the therapeutic implications of these insights.

4.3 Role of Cancer Stem Cells (CSCs) and Metastasis Initiating Cells (MICs)

Cancer stem cells (CSCs) and metastasis initiating cells (MICs) are key drivers of tumor evolution and metastasis, contributing to cancer's complexity and adaptability through plasticity and the ability to self-renew and differentiate. This plasticity enables CSCs to adapt to diverse microenvironmental conditions, facilitating phenotypic transitions that support survival and colonization in distant tissues, enhancing metastatic potential [82]. Integrating physical and biological factors into tumor dynamics models offers a comprehensive understanding of how CSCs and MICs contribute to tumor evolution [84].

Dynamic interactions within the core gene regulatory network significantly influence CSC behavior, driving contributions to tumor evolution and metastasis [72]. These interactions highlight the complexity of CSC behavior, which is not solely a result of genetic variance but an evolutionary trait enhancing survival in fluctuating environments [85]. Moreover, higher CSC densities correlate with increased tumor invasiveness, challenging previous assumptions about their adverse effects on tumor behavior and underscoring their role in enhancing metastatic potential [86].

Exosomes play a critical role in shaping the pre-metastatic niche, facilitating communication between CSCs and the TME, and influencing tumor growth and metastasis through pathways such as immune modulation and vascular changes [87]. Understanding these microenvironmental interactions is crucial for elucidating CSC and MIC behavior, as they are vital for establishing metastatic sites [12].

Future research should focus on developing integrative frameworks to enhance understanding of cancer, particularly the role of CSCs in tumor evolution, to improve therapeutic strategies [74]. Viewing therapy as a population of heterogeneous elementary therapies, rather than a one-size-fits-all approach, may yield a more adaptive and evolutionary response to cancer, potentially enhancing patient outcomes [88]. Additionally, fine-grained simulations of the microenvironment reveal that even small tumors can create diverse ecological niches that drive adaptive evolution of tumor clones [89].

CSCs and MICs are crucial in the metastatic cascade, as their plasticity and dynamic interactions with the TME significantly influence tumor evolution and metastasis. CSCs and MICs exhibit stem-like properties that enable them to endure the challenges of metastasis, including immune evasion and dormancy. Their engagement with TME components—such as fibroblasts, immune cells, and the ECM—facilitates their establishment of supportive niches in distant organs, promoting tumor growth and recurrence after therapy. Understanding these interactions and the molecular mechanisms governing CSC and MIC behavior is essential for developing effective therapeutic strategies aimed at improving outcomes for patients with advanced cancer [12, 90]. Grasping these dynamics is vital for creating targeted therapies that can effectively disrupt the metastatic process and enhance clinical outcomes for ovarian cancer patients.

5 The Role of the Microenvironment

The tumor microenvironment (TME) is integral to cancer biology, involving dynamic interactions between cancer-associated fibroblasts, immune cells, adipocytes, and the extracellular matrix, which influence tumor initiation, progression, and metastasis. These interactions not only drive uncontrolled cell proliferation but also facilitate angiogenesis and inflammation, suggesting potential targets for cancer therapies [91, 11, 12, 13, 14]. The TME shapes the metabolic and phenotypic traits of cancer cells, revealing mechanisms behind tumor development and therapy resistance, thus necessitating innovative targeting strategies.

5.1 Metabolic and Microenvironmental Interactions

Metabolic interactions within the TME are critical to cancer progression as they dictate resource competition among cancer cells, stromal components, and immune cells. This competition drives metabolic reprogramming in cancer cells, enabling adaptation to fluctuating nutrient and oxygen levels necessary for proliferation and invasion [35]. The metabolic plasticity of cancer stem cells (CSCs) further complicates these interactions, supporting their survival and self-renewal, which contributes to tumor heterogeneity and resistance [21]. Spatial heterogeneity within the TME affects resource distribution and invasion dynamics, impacting the evolutionary trajectory of cancer cells [57].

Exosomes, particularly those carrying miRNAs, modulate the TME by transferring molecular signals that alter its metabolic landscape [38]. These exosomal miRNAs have emerged as biomarkers for early detection and metastasis monitoring, highlighting their significance in TME metabolic interplay [10]. However, the dynamic nature of the TME presents challenges in fully understanding its influence on tumor behavior [55]. Autophagy and the acidic microenvironment further enhance tumor cell survival and invasion [69, 92].

The hybrid epithelial-mesenchymal (E/M) phenotype facilitates collective migration, influenced by TME interactions [35]. Mechanical coupling and communication enhance the sensory capabilities of cell collectives, emphasizing the role of physical interactions in tumor progression [75]. Bridging gaps in connecting diverse biological scales remains a challenge, but understanding these interactions is vital for developing therapies that disrupt TME support for cancer progression [14]. Metabolic interactions within the TME, particularly through mutualism, significantly influence cancer progression and tumor growth dynamics [21]. Advanced modeling techniques and genomic data integration can enhance personalized drug target prediction and therapeutic strategies [75].

5.2 Immune Modulation and Therapeutic Implications

Interactions between the immune system and the TME are crucial in determining ovarian cancer progression and therapeutic response. The immune system can both suppress and facilitate metastasis, complicating therapeutic strategy development [93]. The TME modulates immune cell function, creating an immunosuppressive environment that promotes tumor growth [13]. The heterogeneity and dynamic nature of the TME complicate the identification of consistent therapeutic targets, as its composition varies among patients and tumor regions [13]. Tumor-associated macrophages (TAMs), regulatory T cells, and myeloid-derived suppressor cells (MDSCs) contribute to this immunosuppressive milieu, hindering immune-based therapies.

Linking theoretical models of immune-tumor interactions to clinical data remains challenging, underscoring the need for integrative approaches combining computational modeling and empirical data to understand immune modulation dynamics in the TME [94]. Targeting immune components, particularly through reprogramming TAMs to an anti-tumorigenic phenotype, offers a promising therapeutic strategy [95, 13]. Inhibiting MDSC recruitment and activation could enhance therapy efficacy, necessitating a deeper understanding of immune modulation within the TME for innovative therapeutic strategies.

5.3 Therapeutic Targets in the Tumor Microenvironment

The TME's complexity and dynamism are crucial for cancer progression, metastasis, and therapeutic resistance [14]. It includes cancer-associated fibroblasts (CAFs), immune cells, and ECM elements, each contributing to tumor aggressiveness and treatment resistance [12]. Identifying and targeting specific TME components presents promising therapeutic avenues. CAF-derived collagen products, integral to ECM integrity, influence tumor stiffness and facilitate invasion and metastasis [67]. Targeting these products may disrupt the TME's supportive framework, inhibiting tumor progression and enhancing treatment responses.

Advanced modeling approaches highlight cellular migratory activity as a therapeutic target, suggesting that impeding cancer cell migration within the TME could reduce metastatic potential [79]. Biophysical markers associated with tumor aggressiveness and resistance offer further therapeutic targets, as tissue stiffness and cellular mechanical properties provide insights into the TME's biophysical landscape [96].

Future research should explore TME interactions to identify therapeutic targets and develop strategies to manipulate these interactions, potentially overcoming TME challenges and improving cancer patient outcomes [14]. Understanding and targeting TME components and interactions remain critical in the quest for more effective cancer therapies.

6 The Metastatic Niche

6.1 Mechanisms of Niche Formation and Maintenance

Metastatic niches are pivotal for the colonization of cancer cells in distant organs, facilitating the metastatic cascade in ovarian cancer. These specialized microenvironments provide conditions for circulating tumor cells (CTCs) to adhere, survive, and proliferate [27]. The establishment of these niches involves a complex interplay of tumor-derived factors, extracellular vesicles, and host tissue interactions. The pre-metastatic niche (PMN) is particularly influenced by factors from the primary tumor that modify distant organ environments to favor tumor cell colonization [27]. These factors, including cytokines, growth factors, and exosomes, alter the extracellular matrix (ECM), recruit bone marrow-derived cells, and promote angiogenesis, creating a favorable environment for CTCs. Exosomes are crucial in niche formation, transferring oncogenic signals and miRNAs to recipient cells in distant tissues, thereby modulating local microenvironments to support metastatic growth [28].

The maintenance of metastatic niches involves continuous interactions between cancer cells and surrounding stromal and immune components. Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) are key in sustaining an immunosuppressive environment that shields metastatic cells from immune surveillance [29]. These cells, along with other stromal elements, contribute to ECM remodeling and secrete pro-survival signals enhancing metastatic cell fitness [27]. The dynamic nature of metastatic niches poses challenges for therapeutic intervention, as they evolve in response to signals from both the tumor and host tissue. Understanding the molecular and cellular mechanisms of niche formation and maintenance is essential for developing strategies to disrupt these processes and prevent metastasis, potentially inhibiting the metastatic spread of ovarian cancer and improving patient outcomes [28].

6.2 Role of Biomarkers and Predictive Models

Biomarkers and predictive models are crucial for understanding and anticipating metastatic niche formation and cancer spread. These tools provide insights into the molecular and cellular path-

ways underlying metastasis, facilitating early detection and targeted intervention in ovarian cancer. Biomarkers derived from tumor-secreted exosomes and extracellular vesicles are critical indicators of metastatic potential, carrying proteins, nucleic acids, and metabolites that reflect the tumor's biological state and its interaction with the microenvironment. These exosomal biomarkers can indicate pre-metastatic niche establishment by modulating local tissue environments to favor cancer cell colonization [31].

Predictive models, including computational and mathematical frameworks, simulate the complex dynamics of niche formation and metastasis, incorporating data from genomic, proteomic, and metabolomic studies to predict cancer cell dissemination and secondary tumor establishment in distant organs [27]. By integrating variables such as tumor-secreted factors, immune cell interactions, and ECM components, these models offer a comprehensive view of the metastatic process [28]. Advanced techniques like agent-based models and network analysis facilitate the simulation of tumor-stroma interactions and identify key regulatory nodes as potential therapeutic targets [29].

Integrating biomarkers into predictive models enhances their accuracy and clinical utility, allowing for high-risk metastasis patient identification and guiding personalized treatment strategies. For instance, detecting specific miRNAs in circulating exosomes can inform the likelihood of niche formation and metastatic spread, enabling timely therapeutic intervention [30]. Moreover, machine learning algorithms and AI tools have expanded these models' predictive capabilities, facilitating large dataset analysis and novel biomarker identification associated with metastatic progression [31].

Incorporating biomarkers and predictive models into ovarian cancer management holds significant promise for improving patient outcomes through earlier detection and more precise, targeted treatment strategies for metastatic cases. Biomarkers like CA125 and HE4 have proven valuable in differentiating benign from malignant pelvic masses, monitoring treatment responses, and anticipating recurrences, with CA125 levels often rising months before clinical symptoms appear. Advancements in imaging techniques and new biomarker development are expected to enhance diagnostic accuracy and risk stratification, ultimately aiming to reduce mortality rates associated with this often asymptomatic and late-diagnosed cancer [97, 98, 16]. By deepening our understanding of the molecular mechanisms driving niche formation and metastasis, these tools have the potential to significantly improve patient outcomes and alleviate the burden of this aggressive malignancy.

7 Implications for Treatment and Therapy

7.1 Challenges in Detection and Treatment

Ovarian cancer treatment is complicated by diagnostic challenges and therapeutic limitations. Current diagnostic tools, including CA125 testing and imaging, lack sensitivity and specificity, delaying early-stage detection and worsening prognoses [99]. Tumor spatial heterogeneity further complicates treatment by affecting drug distribution and fostering resistance [37]. This heterogeneity extends to the tumor immune microenvironment (TIME), complicating immunotherapy response predictions [7]. The high rate of cell extravasation, with few establishing secondary tumors, underscores the need to understand successful colonization mechanisms [3]. Tumor biophysical property changes impede prognostic marker development, while mutation probability imprecision complicates clonal relatedness determination [96, 61]. An integrative approach combining predictive genomics and personalized treatment strategies is essential for addressing these challenges. Advanced computational models can analyze sequencing data, prioritize driver genes, and enhance cancer biology understanding, improving outcomes through timely diagnosis and targeted therapies [73, 74, 100].

7.2 Drug Resistance Mechanisms

Drug resistance in ovarian cancer arises from genetic mutations, cellular signaling, and microenvironmental factors [40]. Resistance can develop from pre-existing resistant subpopulations and acquired traits during therapy [101]. Epithelial-mesenchymal transition (EMT), particularly partial EMT, enhances invasive and resistant cancer cell traits [45]. Cancer stem cells (CSCs) contribute to resistance due to their heterogeneity and adaptability, complicating recurrence and metastasis [80]. Competitive dynamics within the tumor microenvironment, such as glucose competition, influence tumor behavior [102]. Exosomes mediate drug resistance by transferring resistance traits, although their effects vary across tumors [87]. Tumor electrical properties, like surface charge density, impact

treatment strategies by affecting drug delivery [50]. Complex tumor-immune interactions complicate resistance mechanisms and treatment outcomes [51]. Advancements in automated cancer detection and topological methods show promise in overcoming resistance, enhancing detection accuracy, and offering insights into niche formation [103, 43, 17].

7.3 Innovative Therapeutic Approaches

Emerging strategies in ovarian cancer treatment focus on tumor biology, microenvironment, and resistance interplay. Mathematical modeling and combinational therapies show potential in improving outcomes [92]. Understanding pre-metastatic and metastatic niches informs therapies targeting conditions conducive to cancer spread, potentially impeding metastasis [44]. Novel biomarkers and multibiomarker panels, like exosomal miRNAs, offer improvements in detection and management [38]. Integrating sensing and migration theories can develop comprehensive understandings of tumor invasiveness [80]. Topological analysis and community detection methods identify potential drug targets, leading to innovative approaches [24]. Understanding macrophage behavior in the tumor microenvironment may lead to more effective therapies [10]. Chaotic multi-scale cancer-invasion models suggest interventions based on tumor behavior [5]. Spatial heterogeneity analysis provides insights into cancer dynamics and resistance, suggesting new therapeutic avenues [37]. Integrating these approaches into ovarian cancer treatment holds promise for improving outcomes, with future research exploring neural networks and deep learning for enhanced detection [66]. Identifying spatial patterns among immune cells can inform therapeutic strategies [34].

7.4 Targeting Cancer Stem Cells and Tumor Dynamics

Targeting cancer stem cells (CSCs) and modifying tumor dynamics are crucial for advancing ovarian cancer treatment. CSCs' plasticity complicates interventions, necessitating strategies that inhibit their dynamic equilibrium to reduce tumor heterogeneity and resistance [6]. Advanced technologies like single-cell sequencing and AI can delineate the tumor microenvironment (TME) and identify therapeutic targets [13]. Patient-specific models that integrate clinical data with theoretical frameworks enhance understanding of metastatic disease, enabling treatment customization [61]. Clonality testing can provide insights into CSC dynamics and tumor evolution. Genomics-guided representation learning and feature extraction improve TME subtype classification, optimizing treatment strategies [95, 104, 83, 18]. Integrating these approaches into new combinational therapies can target multiple cancer pathways, addressing existing therapy limitations [60]. Novel tumor models aligned with clinical concepts suggest utility in clinical applications. Future research should develop computational methods to identify cancer driver mutations, explore CSC networks, and model cancer hallmark networks, advancing tumor dynamics understanding and informing targeted therapies. Integrating machine learning and deep learning for data analysis could improve outcomes for ovarian cancer patients, with genetic testing and innovative therapies like PARP inhibitors and immunotherapy evolving to optimize treatment protocols [15, 17, 105, 18].

8 Conclusion

8.1 Emerging Trends and Therapeutic Implications

Advancements in ovarian cancer research underscore the importance of integrating molecular insights with clinical data to enhance patient outcomes, steering the field towards personalized medicine. A deeper understanding of tumor biology and the tumor microenvironment (TME) has led to the development of therapeutic strategies that account for the dynamic interactions within the TME. This progress facilitates novel approaches targeting the supportive elements of the TME, potentially improving therapeutic efficacy and survival rates.

Early detection remains pivotal in improving survival outcomes, with advancements in diagnostic techniques, such as wavelet-based methods, enhancing classification accuracy through the integration of novel and existing features. This progress is crucial for timely intervention and effective management of ovarian cancer. Additionally, exosomes have emerged as valuable tools in liquid biopsy applications, serving as non-invasive biomarkers for cancer diagnosis and monitoring, reflecting the biological state of tumors and their interactions with the microenvironment.

Research into the molecular mechanisms of pre-metastatic niche (PMN) formation is advancing, with significant implications for developing biomarkers that predict metastatic progression and inform therapeutic strategies. The interactions within the (pre)metastatic niche are critical for promoting metastasis, highlighting the potential for therapeutic interventions that target these interactions to impede cancer spread. By focusing on the molecular pathways involved in niche establishment and maintenance, researchers aim to develop targeted therapies that disrupt the metastatic cascade, offering hope for improved patient outcomes in ovarian cancer.

8.2 Future Research Directions

Future research in ovarian cancer should focus on developing innovative biomarkers and screening techniques to enhance early detection and improve patient outcomes. This involves refining engineered biomaterials and enhancing detection methods for early metastasis. Integrating multi-scale models that encompass biochemical signaling and mechanical interactions is essential for advancing our understanding of cancer progression and its influence on collective cell behavior. There is a pressing need to develop therapies that specifically target the tumor microenvironment and investigate the roles of various cellular and molecular components in cancer progression.

Exploring combination therapies that target multiple resistance pathways, alongside the potential of immunotherapy and epigenetic modifications, represents a promising avenue for overcoming therapeutic resistance in ovarian cancer. Research should also focus on the metabolic adaptations of cancer stem cells (CSCs) and metastasis-initiating cells (MICs) to develop targeted therapies that disrupt their contributions to tumor evolution and metastasis. Furthermore, elucidating the molecular mechanisms behind MIC plasticity and developing therapies that effectively target MICs and their regenerative properties is crucial.

The refinement of signal extraction algorithms and the development of standardized protocols for exosomal miRNA analysis are essential for enhancing data reliability and improving the reproducibility of research findings. Moreover, validating expression signature findings in larger, independent cohorts will be critical for translating these insights into clinical practice. Future research should also focus on elucidating the molecular mechanisms of exosome function in pre-metastatic niches and exploring their potential as biomarkers for diagnosis and treatment efficacy.

Future investigations should explore multi-drug resistance dynamics and integrate more realistic vascular networks to improve simulations of patient responses. Additionally, experimental validation of homeostatic pressure measurements and the effects of biochemical environments on tumor growth dynamics could yield new insights into tumor biology. Employing high-dimensional techniques to further characterize the tumor immune microenvironment (TIME) and identify biomarkers predictive of immunotherapy responses is another critical area of focus.

Refining models to incorporate patient-specific data and enhance the connection between experimental results and clinical applications, particularly in personalized medicine, is essential for advancing ovarian cancer treatment. Exploring more complex microenvironments and additional phenotypes to reflect the diverse nature of tumor development will also be crucial for understanding the intricate dynamics of tumor progression. Addressing these research directions will enable significant strides in improving outcomes for ovarian cancer patients.

References

[1] Brett M Reid, Jennifer B Permuth, and Thomas A Sellers. Epidemiology of ovarian cancer: a review. *Cancer biology & medicine*, 14(1):9–32, 2017.

[2] Tijana T. Ivancevic, Murk J. Bottema, and Lakhmi C. Jain. A mathematical model of chaotic attractor in tumor growth and decay, 2008.

[3] Markus Basan, Thomas Risler, Jean-Francois Joanny, Xavier Sastre-Garau, and Jacques Prost. Homeostatic competition drives tumor growth and metastasis nucleation, 2009.

[4] Aseel Shomar, Omri Barak, and Naama Brenner. Cancer progression as a learning process, 2021.

[5] Tijana T. Ivancevic, Murk J. Bottema, and Lakhmi C. Jain. A theoretical model of chaotic attractor in tumor growth and metastasis, 2008.

[6] David M. Gyurko, Daniel V. Veres, Dezso Modos, Katalin Lenti, Tamas Korcsmaros, and Peter Csermely. Adaptation and learning of molecular networks as a description of cancer development at the systems-level: Potential use in anti-cancer therapies, 2013.

[7] Mikhail Binnewies, Edward W Roberts, Kelly Kersten, Vincent Chan, Douglas F Fearon, Miriam Merad, Lisa M Coussens, Dmitry I Gabrilovich, Suzanne Ostrand-Rosenberg, Catherine C Hedrick, et al. Understanding the tumor immune microenvironment (time) for effective therapy. *Nature medicine*, 24(5):541–550, 2018.

[8] Danny R Welch and Douglas R Hurst. Defining the hallmarks of metastasis. *Cancer research*, 79(12):3011–3027, 2019.

[9] Gabriele Bergers and Sarah-Maria Fendt. The metabolism of cancer cells during metastasis. *Nature Reviews Cancer*, 21(3):162–180, 2021.

[10] Mobina Tousian, Christian Solis Calero, and Julio Cesar Perez Sansalvador. Immune cells interactions in the tumor microenvironment, 2024.

[11] Xianjie Jiang, Jie Wang, Xiangying Deng, Fang Xiong, Shanshan Zhang, Zhaojian Gong, Xiayu Li, Ke Cao, Hao Deng, Yi He, et al. The role of microenvironment in tumor angiogenesis. *Journal of Experimental & Clinical Cancer Research*, 39:1–19, 2020.

[12] Maonan Wang, Jingzhou Zhao, Lishen Zhang, Fang Wei, Yu Lian, Yingfeng Wu, Zhaojian Gong, Shanshan Zhang, Jianda Zhou, Ke Cao, et al. Role of tumor microenvironment in tumorigenesis. *Journal of Cancer*, 8(5):761, 2017.

[13] Yi Xiao and Dihua Yu. Tumor microenvironment as a therapeutic target in cancer. *Pharmacology & therapeutics*, 221:107753, 2021.

[14] Borros Arneth. Tumor microenvironment. *Medicina*, 56(1):15, 2019.

[15] Jack Breen, Katie Allen, Kieran Zucker, Pratik Adusumilli, Andy Scarsbrook, Geoff Hall, Nicolas M. Orsi, and Nishant Ravikumar. Artificial intelligence in ovarian cancer histopathology: A systematic review, 2023.

[16] Ghofraan Abdulsalam Atallah, Nor Haslinda Abd. Aziz, Chew Kah Teik, Mohamad Nasir Shafiee, and Nirmala Chandralega Kampan. New predictive biomarkers for ovarian cancer. *Diagnostics*, 11(3):465, 2021.

[17] Lindsay Kuroki and Saketh R Guntupalli. Treatment of epithelial ovarian cancer. *Bmj*, 371, 2020.

[18] Muta Tah Hira, Mohammad A. Razzaque, and Mosharraf Sarker. Ovarian cancer data analysis using deep learning: A systematic review from the perspectives of key features of data analysis and ai assurance, 2023.

[19] Han Chen, Fangqin Lin, and Xionglei He. The degenerative evolution from multicellularity to unicellularity during cancer, 2014.

[20] Asif Newaz, Abdullah Taharat, Md Sakibul Islam, and A. G. M. Fuad Hasan Akanda. An explainable machine learning framework for the accurate diagnosis of ovarian cancer, 2023.

[21] Matteo Turetta, Fabio Del Ben, Giulia Brisotto, Eva Biscontin, Michela Bulfoni, Daniela Cesselli, Alfonso Colombatti, Giacinto Scoles, Giuseppe Gigli, and Loretta L. del Mercato. Emerging technologies for cancer research: Towards personalized medicine with microfluidic platforms and 3d tumor models, 2021.

[22] Penelope M Webb and Susan J Jordan. Epidemiology of epithelial ovarian cancer. *Best practice & research Clinical obstetrics & gynaecology*, 41:3–14, 2017.

[23] Aus Tariq Ali, Osamah Al-Ani, and Faisal Al-Ani. Epidemiology and risk factors for ovarian cancer. *Menopause Review/Przegląd Menopauzalny*, 22(2):93–104, 2023.

[24] Keilash Chirom, Md. Zubbair Malik, Pallavi Somvanshi, and R. K. Brojen Singh. Network medicine in ovarian cancer: Topological properties to drug discovery, 2021.

[25] Jawad Fares, Mohamad Y Fares, Hussein H Khachfe, Hamza A Salhab, and Youssef Fares. Molecular principles of metastasis: a hallmark of cancer revisited. *Signal transduction and targeted therapy*, 5(1):28, 2020.

[26] Qiyao Peng, Fred J Vermolen, and Daphne Weihs. Physical confinement and cell proximity increase cell migration rates and invasiveness: A mathematical model of cancer cell invasion through flexible channels, 2022.

[27] Yuhang Wang, Jiachi Jia, Fuqi Wang, Yingshuai Fang, Yabing Yang, Quanbo Zhou, Weitang Yuan, Xiaoming Gu, Junhong Hu, and Shuaixi Yang. Pre-metastatic niche: formation, characteristics and therapeutic implication. *Signal Transduction and Targeted Therapy*, 9(1):236, 2024.

[28] Ginevra Doglioni, Sweta Parik, and Sarah-Maria Fendt. Interactions in the (pre) metastatic niche support metastasis formation. *Frontiers in oncology*, 9:219, 2019.

[29] Yungang Wang, Yanxia Ding, Naizhou Guo, and Shengjun Wang. Mdscs: key criminals of tumor pre-metastatic niche formation. *Frontiers in immunology*, 10:172, 2019.

[30] Brian A Aguado, Grace G Bushnell, Shreyas S Rao, Jacqueline S Jeruss, and Lonnie D Shea. Engineering the pre-metastatic niche. *Nature biomedical engineering*, 1(6):0077, 2017.

[31] Héctor Peinado, Haiying Zhang, Irina R Matei, Bruno Costa-Silva, Ayuko Hoshino, Goncalo Rodrigues, Bethan Psaila, Rosandra N Kaplan, Jacqueline F Bromberg, Yibin Kang, et al. Pre-metastatic niches: organ-specific homes for metastases. *Nature Reviews Cancer*, 17(5):302–317, 2017.

[32] Jianan Zhuyan, Mingyu Chen, Tianhao Zhu, Xunxia Bao, Timing Zhen, Kaichen Xing, Qiubo Wang, and Sibo Zhu. Critical steps to tumor metastasis: alterations of tumor microenvironment and extracellular matrix in the formation of pre-metastatic and metastatic niche. *Cell & Bioscience*, 10:1–9, 2020.

[33] R J Seager, Cynthia Hajal, Fabian Spill, Roger D Kamm, and Muhammad H Zaman. Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression, 2017.

[34] Jonatan A. González, Julia Wrobel, Simon Vandekar, and Paula Moraga. Analysing spatial point patterns in digital pathology: immune cells in high-grade serous ovarian carcinomas, 2023.

[35] Varvara Petrova, Margherita Annicchiarico-Petruzzelli, Gerry Melino, and Ivano Amelio. The hypoxic tumour microenvironment. *Oncogenesis*, 7(1):10, 2018.

[36] Sounak Sadhukhan and S. K. Basu. Tumour induced angiogenesis and its simulation, 2019.

[37] Feng Fu, Martin A. Nowak, and Sebastian Bonhoeffer. Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy, 2014.

[38] Zhenqiang Sun, Ke Shi, Shuaixi Yang, Jinbo Liu, Quanbo Zhou, Guixian Wang, Junmin Song, Zhen Li, Zhiyong Zhang, and Weitang Yuan. Effect of exosomal mirna on cancer biology and clinical applications. *Molecular cancer*, 17(1):147, 2018.

[39] Quirine J. S. Braat, Cornelis Storm, and Liesbeth M. C. Janssen. Formation of motile cell clusters in heterogeneous model tumors: the role of cell-cell alignment, 2024.

[40] Philip Gerlee, Eunjung Kim, and Alexander R. A. Anderson. Bridging scales in cancer progression: Mapping genotype to phenotype using neural networks, 2014.

[41] David Basanta, Haralambos Hatzikirou, and Andreas Deutsch. Studying the emergence of invasiveness in tumours using game theory, 2008.

[42] Olga Zolotareva, Karen Legler, Olga Tsoy, Anna Esteve, Alexey Sergushichev, Vladimir Sukhov, Jan Baumbach, Kathrin Eylmann, Minyue Qi, Malik Alawi, Stefan Kommoss, Barbara Schmalfeldt, and Leticia Oliveira-Ferrer. Transcriptome signature for the identification of bevacizumab responders in ovarian cancer, 2025.

[43] Ling Wang, Xin Wang, Xueping Zhu, Lin Zhong, Qingxiu Jiang, Ya Wang, Qin Tang, Qiaoling Li, Cong Zhang, Haixia Wang, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. *Molecular Cancer*, 23(1):66, 2024.

[44] M. Ali Al-Radhawi and Eduardo D. Sontag. Analysis of a reduced model of epithelial-mesenchymal fate determination in cancer metastasis as a singularly-perturbed monotone system, 2020.

[45] Mohit Kumar Jolly, Marcelo Boareto, Bin Huang, Dongya Jia, Mingyang Lu, Jose N Onuchic, Herbert Levine, and Eshel Ben-Jacob. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis, 2015.

[46] Uri Ben-David, Rameen Beroukhim, and Todd R Golub. Genomic evolution of cancer models: perils and opportunities. *Nature Reviews Cancer*, 19(2):97–109, 2019.

[47] Julien Varennes and Andrew Mugler. Sense and sensitivity: physical limits to multicellular sensing, migration and drug response, 2016.

[48] Jorge A. González, M. Acanda, Z. Akhtar, D. Andrews, J. I. Azqueta, E. Bass, A. Bellorín, J. Couso, Mónica A. García-Ñustes, Y. Infante, S. Jiménez, L. Lester, L. Maldonado, Juan F. Marín, L. Pineda, I. Rodríguez, C. C. Tamayo, D. Valdes, and L. Vázquez. New combinational therapies for cancer using modern statistical mechanics, 2019.

[49] Ahmed M. Fouad. Dynamical stability analysis of tumor growth and invasion: A reaction-diffusion model, 2019.

[50] Henry Bory Prevez, Argenis Adrian Soutelo Jimenez, Eduardo José Roca Oria, José Alejandro Heredia Kindelán, Maraelys Morales González, Narciso Antonio Villar Goris, Nibaldo Hernández Mesa, Victoriano Gustavo Sierra González, Yenia Infantes Frometa, Juan Ignacio Montijano Torcal, and Luis Enrique Bergues Cabrales. Simulations of surface charge density changes during the untreated solid tumor growth, 2022.

[51] Elena Piretto, Marcello Delitala, Peter S. Kim, and Federico Frascoli. Effects of mutations and immunogenicity on outcomes of anti-cancer therapies for secondary lesions, 2021.

[52] Bernadette J. Stolz, Jagdeep Dhesi, Joshua A. Bull, Heather A. Harrington, Helen M. Byrne, and Iris H. R. Yoon. Relational persistent homology for multispecies data with application to the tumor microenvironment, 2023.

[53] Thomas S. Deisboeck and Zhihui Wang. Cancer dissemination: A consequence of limited carrying capacity?, 2006.

[54] caterina Guiot, Piero Giorgio Degiorgis, Pier Paolo Delsanto, Pietro Gabriele, and Thomas S. Deisboeck. Does tumor growth follow a 'universal law'?, 2003.

[55] Mengli Hao, Jinqiao Duan, Renming Song, and Wei Xu. Asymmetric non-gaussian effects in a tumor growth model with immunization, 2012.

[56] G. Dattoli, G. Dattoli, S. Licciardi, C. Guiot, and T. S. Deisboeck. Capillary network, cancer and kleiber law, 2014.

[57] Nikolaos Sfakianakis, Anotida Madzvamuse, and Mark A. J. Chaplain. A hybrid multiscale model for cancer invasion of the extracellular matrix, 2018.

[58] Sebastien Benzekry, Dominique Barbolosi, Assia Benabdallah, Florence Hubert, and Philip Hahnfeldt. Quantitative analysis of the tumor/metastasis system and its optimal therapeutic control, 2013.

[59] Kenneth J. Pienta, Bruce Robertson, Donald S. Coffey, and Russell S. Taichman. The cancer diaspora: Metastasis beyond the seed and soil hypothesis, 2013.

[60] Sebastien Benzekry. Mathematical analysis of a two-dimensional population model of metastatic growth including angiogenesis, 2010.

[61] Irina Ostrovnaya, Venkatraman E. Seshan, and Colin B. Begg. Using somatic mutation data to test tumors for clonal relatedness, 2015.

[62] Dongya Jia, Jun Hyoung Park, Harsimran Kaur, Kwang Hwa Jung, Sukjin Yang, Shubham Tripathi, Madeline Galbraith, Youyuan Deng, Mohit Kumar Jolly, Benny Abraham Kaipparettu, Jose N. Onuchic, and Herbert Levine. Towards decoding the coupled decision-making of metabolism and epithelial-mesenchymal transition in cancer, 2020.

[63] Katrin Talkenberger, Elisabetta Ada Cavalcanti-Adamda, Andreas Deutsch, and Anja Voss-Böhme. Amoeboid-mesenchymal migration plasticity promotes invasion only in complex heterogeneous microenvironments, 2017.

[64] András Szabó and Roeland M. H. Merks. Blood vessel tortuosity selects against evolution of agressive tumor cells in confined tissue environments: a modeling approach, 2017.

[65] Jingjie Yang, Heidi Fang, Jagdeep Dhesi, Iris H. R. Yoon, Joshua A. Bull, Helen M. Byrne, Heather A. Harrington, and Gillian Grindstaff. Topological classification of tumour-immune interactions and dynamics, 2023.

[66] Bliss Singhal and Fnu Pooja. Metastatic breast cancer prognostication through multimodal integration of dimensionality reduction algorithms and classification algorithms, 2023.

[67] Neel I Nissen, Morten Karsdal, and Nicholas Willumsen. Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. *Journal of Experimental & Clinical Cancer Research*, 38(1):115, 2019.

[68] Jadwiga Jablonska, Stephan Lang, Ronit Vogt Sionov, and Zvi Granot. The regulation of pre-metastatic niche formation by neutrophils. *Oncotarget*, 8(67):112132, 2017.

[69] Szabolcs Suveges, Raluca Eftimie, and Dumitru Trucu. Re-polarisation of macrophages within a multi-scale moving boundary tumour invasion model, 2021.

[70] Claudia Peitzsch, Anna Tyutyunnykova, Klaus Pantel, and Anna Dubrovska. Cancer stem cells: The root of tumor recurrence and metastases. In *Seminars in cancer biology*, volume 44, pages 10–24. Elsevier, 2017.

[71] Razvan Tudor Radulescu. Oncoprotein metastasis disjoined, 2007.

[72] Chong Yu, Qiong Liu, Cong Chen, and Jin Wang. Quantification of the underlying mechanisms and relationship among cancer, metastasis and differentiation/development, 2018.

[73] Edwin Wang. Understanding genomic alterations in cancer genomes using an integrative network approach, 2014.

[74] Mona Nourbakhsh, Kristine Degn, Astrid Saksager, Matteo Tiberti, and Elena Papaleo. Prediction of cancer driver genes and mutations: the potential of integrative computational frameworks, 2023.

[75] Lu Peng, Dumitru Trucu, Ping Lin, Alastair Thompson, and Mark A. J. Chaplain. A multiscale mathematical model of tumour invasive growth, 2016.

[76] Navid Mohammad Mirzaei and Leili Shahriyari. Modeling cancer progression: An integrated workflow extending data-driven kinetic models to bio-mechanical pde models, 2023.

[77] Branislav Brutovsky and Denis Horvath. Towards inverse modeling of intratumoral heterogeneity, 2015.

[78] Adrien Hallou, Joel Jennings, and Alexandre Kabla. Cancer metastasis: Collective invasion in heterogeneous multicellular systems, 2014.

[79] Bartlomiej Waclaw, Ivana Bozic, Meredith E. Pittman, Ralph H. Hruban, Bert Vogelstein, and Martin A. Nowak. Spatial model predicts dispersal and cell turnover cause reduced intra-tumor heterogeneity, 2015.

[80] Chong Yu, Qiong Liu, Cong Chen, and Jin Wang. A physical mechanism of heterogeneity in stem cell, cancer and cancer stem cell, 2019.

[81] Alexander Davis, Ruli Gao, and Nicholas Navin. Tumor evolution: Linear, branching, neutral or punctuated? *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 1867(2):151–161, 2017.

[82] Caterina A. M. La Porta and Stefano Zapperi. Complexity in cancer stem cells and tumor evolution: towards precision medicine, 2017.

[83] Magdalena Wysocka, Oskar Wysocki, Marie Zufferey, Dónal Landers, and André Freitas. A systematic review of biologically-informed deep learning models for cancer: fundamental trends for encoding and interpreting oncology data, 2023.

[84] P. K. Biswas and M. T. T. Pacheco. Correspondence between time-evolution dynamics of a tumor and an attractively interacting bose-einstein condensate with feeding and dissipation, 2003.

[85] B. Brutovsky and D. Horvath. Structure of intratumor heterogeneity: Is cancer hedging its bets?, 2013.

[86] Youness Azimzade, Abbas Ali Saberi, and Muhammad Sahimi. Role of the interplay between the internal and external conditions in invasive behavior of tumors, 2018.

[87] Yaxin Guo, Xiang Ji, Jinbo Liu, Dandan Fan, Quanbo Zhou, Chen Chen, Weiwei Wang, Guixian Wang, Haijiang Wang, Weitang Yuan, et al. Effects of exosomes on pre-metastatic niche formation in tumors. *Molecular Cancer*, 18:1–11, 2019.

[88] Branislav Brutovsky and Denis Horvath. In silico implementation of evolutionary paradigm in therapy design: Towards anti-cancer therapy as darwinian process, 2019.

[89] Thierry Fredrich, Heiko Rieger, Roberto Chignola, and Edoardo Milotti. Fine-grained simulations of the microenvironment of vascularized tumours, 2019.

[90] Joan Massague and Karuna Ganesh. Metastasis-initiating cells and ecosystems. *Cancer discovery*, 11(4):971–994, 2021.

[91] Roghayyeh Baghban, Leila Roshangar, Rana Jahanban-Esfahlan, Khaled Seidi, Abbas Ebrahimi-Kalan, Mehdi Jaymand, Saeed Kolahian, Tahereh Javaheri, and Peyman Zare. Tumor microenvironment complexity and therapeutic implications at a glance. *Cell Communication and Signaling*, 18:1–19, 2020.

[92] Jesús J. Bosque, Gabriel F. Calvo, and María Cruz Navarro. Modelling the effect of vascular status on tumour evolution and outcome after thermal therapy, 2022.

[93] Louise ME Janssen, Emma E Ramsay, Craig D Logsdon, and Willem W Overwijk. The immune system in cancer metastasis: friend or foe? *Journal for immunotherapy of cancer*, 5:1–14, 2017.

[94] Jacob G. Scott, Philip Gerlee, David Basanta, Alexander G. Fletcher, Philip K. Maini, and Alexander RA Anderson. Mathematical modeling of the metastatic process, 2013.

[95] Fangliangzi Meng, Hongrun Zhang, Ruodan Yan, Guohui Chuai, Chao Li, and Qi Liu. Genomics-guided representation learning for pathologic pan-cancer tumor microenvironment subtype prediction, 2024.

[96] Anja Madleine Markl, Daniel Nieder, Diana Isabel Sandoval-Bojorquez, Anna Taubenberger, Jean-François Berret, Artur Yakimovich, Eduardo Sergio Oliveros-Mata, Larysa Baraban, and Anna Dubrovska. Heterogeneity of tumor biophysical properties and their potential role as prognostic markers, 2024.

[97] Rosemarie Forstner. Early detection of ovarian cancer. *European radiology*, 30(10):5370–5373, 2020.

[98] Wei-Lei Yang, Zhen Lu, and Robert C Bast Jr. The role of biomarkers in the management of epithelial ovarian cancer. *Expert review of molecular diagnostics*, 17(6):577–591, 2017.

[99] Dixon Vimalajeewa, Scott Alan Bruce, and Brani Vidakovic. Early detection of ovarian cancer by wavelet analysis of protein mass spectra, 2022.

[100] Edwin Wang, Naif Zaman, Shauna Mcgee, Jean-Sébastien Milanese, Ali Masoudi-Nejad, and Maureen O'Connor. Predictive genomics: A cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data, 2014.

[101] Jana L. Gevertz, Zahra Aminzare, Kerri-Ann Norton, Judith Perez-Velazquez, Alexandria Volkening, and Katarzyna A. Rejniak. Emergence of anti-cancer drug resistance: Exploring the importance of the microenvironmental niche via a spatial model, 2014.

[102] Irina Kareva. Competition driven cancer immunoediting, 2014.

[103] Ami B. Shah, Katarzyna A. Rejniak, and Jana L. Gevertz. Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases, 2016.

[104] Jaya Thomas and Lee Sael. Multi-kernel ls-svm based bio-clinical data integration: Applications to ovarian cancer, 2017.

[105] Dina Mikdadi, Kyle A O'Connell, Philip J Meacham, Madeleine A Dugan, Michael O Ojiere, Thaddeus B Carlson, and Juergen A Klenk. Applications of artificial intelligence (ai) in ovarian cancer, pancreatic cancer, and image biomarker discovery. *Cancer Biomarkers*, 33(2):173–184, 2022.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.